Table 2.

Follow-up at 12-18 months after initiation of EmmaCOPD (n=29).

Outcomes	Results
Follow-up duration (days), median (IQR)	587.0 (372.0-594.0)
Mortality (yes), n (%)	3 (10)
Number of mild exacerbationsa, median (IQR)	0.0 (0.0 to 0.0)
Number of moderate exacerbationsb, median (IQR)	0.0 (0.0 to 0.0)
Number of severe exacerbationsc, median (IQR)	1.0 (0.0 to 2.0)
Total number of exacerbations, median (IQR)	1.0 (0.0 to 2.0)
Hospital admission (days), median (IQR)	2.0 (0.0 to 4.0)
Change in CCQd, median (IQR)e	0.3 (–0.4 to 0.9)

^aMild exacerbation: change in COPD medication.

^bModerate exacerbation: course of corticosteroids and/or antibiotics.

^cSevere exacerbation: hospital admission.

^dCCQ: clinical chronic obstructive pulmonary disease questionnaire.

^en=28, data missing for 1 participant.